Interaction between Atropine and Pralidoxime
Minor
Synergy
| ID | DDInter136 and DDInter1503 |
| Interaction | Pralidoxime and other drugs within the family of compounds called oximes, such as obidoxime, may potentiate the pharmacologic effects of atropine. Signs of atropinization such as flushing, mydriasis, tachycardia, and dry mouth and nose may occur earlier than expected during coadministration with pralidoxime relative to administration of atropine alone, particularly if the total dose of atropine has been large and the administration of pralidoxime was delayed. Clinicians should be aware of the potential interaction and monitor patients as appropriate. Pralidoxime may be used in conjunction with atropine in the treatment of organophosphate insecticide poisoning and nerve agent poisoning in terrorism or chemical warfare. |
| Management | - |
| References | |
| Alternative for Atropine |
S01F
Ketorolac
Scopolamine
Ephedrine (nasal)
Methscopolamine
Phenylephrine (nasal)
Homatropine (ophthalmic)
Phenylephrine (ophthalmic)
Phenylephrine (otic)
Phenylephrine (topical)
Tropicamide (ophthalmic)
Cyclopentolate (ophthalmic)
More
|
| Alternative for Pralidoxime |
V03A
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.